V
Vineet D. Menachery
Researcher at University of Texas Medical Branch
Publications - 145
Citations - 16701
Vineet D. Menachery is an academic researcher from University of Texas Medical Branch. The author has contributed to research in topics: Coronavirus & Virus. The author has an hindex of 49, co-authored 126 publications receiving 10613 citations. Previous affiliations of Vineet D. Menachery include Texas Medical Center & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Spike mutation D614G alters SARS-CoV-2 fitness.
Jessica A. Plante,Yang Liu,Jianying Liu,Hongjie Xia,Bryan A. Johnson,Kumari G. Lokugamage,Xianwen Zhang,Antonio E. Muruato,Jing Zou,Camila R. Fontes-Garfias,Divya Mirchandani,Dionna Scharton,John P. Bilello,Zhiqiang Ku,Zhiqiang An,Birte Kalveram,Alexander N. Freiberg,Vineet D. Menachery,Xuping Xie,Kenneth S. Plante,Scott C. Weaver,Pei Yong Shi +21 more
TL;DR: Hamsters infected with SARS-CoV-2 expressing spike D614G (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.
Journal ArticleDOI
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan,Amy C. Sims,Rachel L. Graham,Vineet D. Menachery,Lisa E. Gralinski,James Brett Case,Sarah R. Leist,Krzysztof Pyrc,Joy Y. Feng,Iva Trantcheva,Roy Bannister,Yeojin Park,Darius Babusis,Michael O. Clarke,Richard L. Mackman,Jamie E. Spahn,Christopher A. Palmiotti,Dustin Siegel,Adrian S. Ray,Tomas Cihlar,Robert Jordan,Mark R. Denison,Ralph S. Baric +22 more
TL;DR: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses in vitro and in vivo and may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.
Journal ArticleDOI
Return of the Coronavirus: 2019-nCoV.
TL;DR: The emergence of a novel coronavirus (2019-nCoV) has awakened the echoes of SARS-CoV from nearly two decades ago, but with technological advances and important lessons gained from previous outbreaks, perhaps the world is better equipped to deal with the most recent emergent group 2B coronav virus.
Journal ArticleDOI
A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
Vineet D. Menachery,Boyd Yount,Kari Debbink,Sudhakar Agnihothram,Lisa E. Gralinski,Jessica A. Plante,Rachel L. Graham,Trevor Scobey,Xing Yi Ge,Eric F. Donaldson,Scott H. Randell,Antonio Lanzavecchia,Wayne A. Marasco,Zhengli Li Shi,Ralph S. Baric +14 more
TL;DR: A potential risk of SARS-CoV re-emergence from viruses currently circulating in bat populations is suggested, and robust viral replication both in vitro and in vivo is demonstrated.
Journal ArticleDOI
Evasion of Type I Interferon by SARS-CoV-2.
Hongjie Xia,Zengguo Cao,Xuping Xie,Xianwen Zhang,John Yun Chung Chen,Hualei Wang,Vineet D. Menachery,Ricardo Rajsbaum,Pei Yong Shi +8 more
TL;DR: Insight is provided on SARS-CoV-2 evasion of IFN-I response and its potential impact on viral transmission and pathogenesis.